STARC Spotlight: Skin Toxicities & Tumors in Pediatric Cancer Care

About this episode

This episode discusses skin toxicities and tumors in pediatric cancer care, focusing on prevention and management strategies.

Skin reactions during pediatric cancer treatment can be painful, stigmatizing, and sometimes threaten a child’s ability to stay on therapy. In this episode of PeDRA Pearls , Dr. Christina Boull and Dr. Rebecca Levy discuss PeDRA's Skin Tumors and Reactions to Cancer Therapies (STARC) Focused Study Group and its work to prevent, recognize, and manage these toxicities. They highlight multicenter efforts spanning photosensitivity prevention, survivorship outcomes, and targeted therapy side effects—including MEK inhibitor–associated mucocutaneous toxicities—plus the need for stronger derm–onc collaboration, better trial reporting, and evidence-based consensus guidelines. Click here for more information.

People in this episode

Guests: Dr. Christina Boull, Dr. Rebecca Levy

Topics covered

• pediatric cancer care
• skin toxicities
• tumors
• cancer therapies
• dermatology
• clinical collaboration

Keywords

• pediatric dermatology
• skin reactions
• cancer treatment
• photosensitivity
• survivorship outcomes
• targeted therapy
• mucocutaneous toxicities

Mentioned in this episode

Organizations: PeDRA, Skin Tumors and Reactions to Cancer Therapies (STARC), MEK

More episodes of PeDRA Pearls

• Beyond Alopecia: Advancing Pediatric Hair Disorders Research · June 8, 2026 · 37 min
• Pediatric Atopic Dermatitis: New Guidelines, New Treatments, New Questions · June 1, 2026 · 52 min
• PeDRA at SID - Key Takeaways from the 2026 Meeting · May 21, 2026 · 35 min
• PeDRA at SID - Reflections with Lynn Petukhova, PhD · May 20, 2026 · 16 min
• PeDRA at SID - A Patient Advocacy Perspective · May 20, 2026 · 11 min
• PeDRA at SID - Poster Interviews · May 20, 2026 · 38 min